ZVSA
ZyVersa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.05
+0.00%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$0.05
From 52W high−82.22%
Volume77962.00
Market cap$3.72M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$0.05
From 52W high
−82.22%
Volume
77962.00
Market cap
$3.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−36.5x
P/E (TTM)
—
RSI (14)
24.5
MomentumView details →
1D Return
+0.00%
YTD Return
−64.18%
SummaryUpdated Mar 1, 2026
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) is a clinical-stage biopharmaceutical company founded and headquartered in Weston, Florida. The company went public in February 2022 and focuses on developing novel therapeutic treatments for renal (kidney) and inflammatory diseases. As a pre-revenue biotechnology company, ZyVersa is currently advancing two primary drug candidates through clinical development: VAR 200 for kidney diseases and IC 100 for inflammatory conditions.
Similar companies
Latest newsMore news →
No recent news for ZVSA.